BiOasis, UBC to Develop Alzheimer's PGx Test | GenomeWeb

NEW YORK (GenomeWeb News) – BiOasis Technologies and the University of British Columbia will collaborate to develop and test a biomarker assay for Alzheimer's disease, the company said today.

The goal of the collaboration is to develop and test concentration levels of the p97 protein in blood using an enzyme-linked immunosorbent assay test to diagnose Alzheimer's. The firms said that the "quick and accurate" test would help doctors diagnose the disease and monitor the effectiveness of therapeutics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.